Showing posts with label Lapatinib. Show all posts
Showing posts with label Lapatinib. Show all posts
Thursday, February 16, 2017

Novel combination therapy shows strong response in phase 1 trial

›
In continuation of my update on Sorafenib , Premetrexed ,   Vandetanib "Though phase 1 studies are designed to evaluate the safety ...
Friday, November 27, 2015

Research: Epigenetic factor reduces sensitivity of breast cancer cells to common cancer drug

›
,  In continuation of my update on  lapatinib A surprising, paradoxical relationship between a tumor suppressor molecule and a...
Friday, July 17, 2015

New combination therapy holds promise for treating HER2-positive breast cancer

›
Resistance to therapy is a major problem in the cancer field. Even when a treatment initially works, the tumors often find ways around the...
Thursday, December 27, 2012

Lapatinib benefits found for HER2-positive early-stage patients

›
In continuation of my update on Lapatinib Lapatinib benefits found for HER2-positive early-stage patients
Friday, August 3, 2012

Novel way to treat drug-resistant brain tumor cells

›
In continuation of my update on Lapatinib Research by Dr. Paul Clark, a scientist in Kuo's lab and the study's lead author, ...
Friday, February 5, 2010

FDAs approval of Lapatinib in combination with Letrozole to treat breast cancer...

›
In my earlier blog, I mentioned about the combination of Lapatinib and Trastuzumab for breast cancer treatment. Now FDA has  approved...
Tuesday, December 15, 2009

Combination of Lapatinib and Trastuzumab a better treatment for breast cancer....

›
Lapatinib or lapatinib ditosylate is an orally active chemotherapeutic drug treatment for solid tumours such as breast cancer. Patie...